This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Intersect ENT (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, will visit the NASDAQ MarketSite in Times Square in celebration of its initial public offering (IPO) which will occur today, July 24, 2014.
In honor of the occasion,
Lisa Earnhardt, Chief Executive Officer will ring the Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Thursday, July 24, 2014 – 9:15 a.m. to 9:30 a.m. ET
Intersect ENT Media Contact: Jeri Hilleman (650) 641-2105
email@example.comNASDAQ MarketSite: Christine Barna (646) 441-5310
Christine.Barna@nasdaqomx.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For photos from ceremonies and events visit our Instagram Page:
For news tweets, please visit our Twitter page at:
For exciting viral content and ceremony photos visit Tumblr Page:
A webcast of the NASDAQ Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Intersect ENT (Nasdaq:XENT):
Intersect ENT, Inc. is a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. Intersect ENT's drug-eluting bioabsorbable implant technology enables targeted and sustained release of therapeutic agents. Intersect ENT's initial products, PROPEL and PROPEL mini, are the first and only drug-eluting implants approved for use in patients with chronic sinusitis. Use of the PROPEL implants is clinically proven to improve surgical outcomes by maintaining the open pathways created in surgery and reducing the need for oral steroids and additional surgical procedures. In addition, Intersect ENT is developing new, less invasive and more cost-effective drug-eluting bioabsorbable treatment options for the management of chronic sinusitis in the physician office setting to provide benefits for patients, physicians and payors.